SmartNuclide
Vision and Mission
To be the most valuable radiopharmaceutical company in China, and one of the world's leaders.
Bring new hope to patients by developing the most innovative radioactive diagnostic and therapeutic products.
MoreResearch and Development
Committed to the development, production and commercialization of diagnostic and therapeutic drugs in the field of nuclear medicine.
Product Pipeline
We have built a series of R&D pipelines for radiopharmaceutical drugs, including recombinant proteins, imaging and radiotherapeutic drugs.
- Recombinant proteins
- Targeted Radionuclide Imaging
- Targeted Radionuclide Therapy
Targeted Radionuclide Imaging
For diagnostic applications radioisotopes with short half-lives are used. With highly sensitive molecular imaging technologies like PET or SPECT, pictures of organs and lesions at molecular and cellular levels.
- SNA002(PD-L1)
- SNA006(CD8 T cell)
rhTSH
Recombinant Human Thyroid Stimulating Hormone
rhTSH is a recombinant protein used to increase serum TSH level in patients diagnosed with well-differentiated thyroid cancer (DTC)
More
Suzhou Smart Nuclide Pharmaceutical Technology Company was founded in 2015, providing innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights...
MoreR&D
We have set up four industry-leading platforms basing on the single domain antibody .

Articles
Related articles have been published on many influential journals by the R&D team from Smart Nuclide.Relevant research papers of SNA002 have been accepted in the Journal of Nuclear Medicine, which represents the highest level of the radiopharmaceuticals.
Investors














Partners
We are adhering to the concept of innovation and strengthening cooperation with universities, research institutes and hospitals , with a view to providing patients with the most innovative diagnostic and therapeutic products. At present, we have established cooperation with a number of institutions.
















